282 related articles for article (PubMed ID: 17239313)
1. Adjuvant therapy for high-risk renal cell carcinoma patients.
Kunkle DA; Haas NB; Uzzo RG
Curr Urol Rep; 2007 Jan; 8(1):19-30. PubMed ID: 17239313
[TBL] [Abstract][Full Text] [Related]
2. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma.
Smaldone MC; Fung C; Uzzo RG; Haas NB
Hematol Oncol Clin North Am; 2011 Aug; 25(4):765-91. PubMed ID: 21763967
[TBL] [Abstract][Full Text] [Related]
4. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
[TBL] [Abstract][Full Text] [Related]
5. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
Chaudhary UB; Hull GW
Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
Gharib KE
Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
[No Abstract] [Full Text] [Related]
8. May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials.
Messina C; Zanardi E; Boccardo F
Anticancer Agents Med Chem; 2017; 17(12):1633-1643. PubMed ID: 28270065
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma.
Whang YE; Godley PA
Curr Opin Oncol; 2003 May; 15(3):213-6. PubMed ID: 12778014
[TBL] [Abstract][Full Text] [Related]
10. [New therapeutic opportunities in metastatic renal cell carcinoma].
Buess M
Praxis (Bern 1994); 2009 Apr; 98(9):481-6. PubMed ID: 19404907
[TBL] [Abstract][Full Text] [Related]
11. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.
Lam JS; Shvarts O; Leppert JT; Pantuck AJ; Figlin RA; Belldegrun AS
J Urol; 2005 Aug; 174(2):466-72; discussion 472; quiz 801. PubMed ID: 16006866
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis.
Riaz IB; Faridi W; Husnain M; Malik SU; Sipra QUAR; Gondal FR; Xie H; Yadav S; Kohli M
Mayo Clin Proc; 2019 Aug; 94(8):1524-1534. PubMed ID: 31303430
[TBL] [Abstract][Full Text] [Related]
13. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.
Lee BH; Feifer A; Feuerstein MA; Benfante NE; Kou L; Yu C; Kattan MW; Russo P
Eur Urol Focus; 2018 Jan; 4(1):100-105. PubMed ID: 28753780
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma in children and adolescence: our experience.
Kumar S; Sharma P; Pratap J; Tiwari P; Bera MK; Kundu AK
Afr J Paediatr Surg; 2014; 11(2):101-4. PubMed ID: 24841006
[TBL] [Abstract][Full Text] [Related]
15. Multi-modal treatment for metastatic renal cancer: the role of surgery.
Russo P
World J Urol; 2010 Jun; 28(3):295-301. PubMed ID: 20364382
[TBL] [Abstract][Full Text] [Related]
16. Management of locally advanced renal cell carcinoma.
Rodriguez A; Sexton WJ
Cancer Control; 2006 Jul; 13(3):199-210. PubMed ID: 16885916
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma.
Wood E; Donin N; Shuch B
Urol Clin North Am; 2020 Aug; 47(3):345-358. PubMed ID: 32600536
[TBL] [Abstract][Full Text] [Related]
18. High-dose interleukin-2 in metastatic renal cell carcinoma.
Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
[No Abstract] [Full Text] [Related]
19. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.
May M; Brookman-May S; Hoschke B; Gilfrich C; Kendel F; Baxmann S; Wittke S; Kiessig ST; Miller K; Johannsen M
Cancer Immunol Immunother; 2010 May; 59(5):687-95. PubMed ID: 19876628
[TBL] [Abstract][Full Text] [Related]
20. Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival.
Abu-Ghanem Y; Ramon J; Berger R; Kaver I; Fridman E; Leibowitz-Amit R; Dotan ZA
World J Surg Oncol; 2017 Nov; 15(1):193. PubMed ID: 29096642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
